Dan Kawamori

Author Correction: Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance

Chong Wee Liew, Jérémie Boucher, Jit Kong Cheong, Cécile Vernochet et autres

us, sg, es, fr, de (code pays fourni par la source)

1807-P: Elucidation of the Regulatory Mechanism of PPARα in Pancreatic Islet Cell Differentiation Derived from Human iPS Cells

Hiroki Yamaguchi, Shugo Sasaki, Masatomo Takahashi, Yoshihiro Izumi et autres

Introduction and Objective: Differentiating pluripotent stem cells into pancreatic β cells holds promise for diabetes treatment, yet improving differentiation efficiency and insulin secretion remains challenging. Our previous research found that fatty acid synthesis genes (Acly, Mlxipl) are highly expressed in immature β …

Imeglimin, unlike metformin, does not perturb differentiation of human induced pluripotent stem cells towards pancreatic β‐like cells and rather enhances gain in β cell identity gene sets

Tasuku Imada, Shugo Sasaki, Hiroki Yamaguchi, Ayaka Ueda et autres

AIMS/INTRODUCTION: Metformin treatment for hyperglycemia in pregnancy (HIP) beneficially improves maternal glucose metabolism and reduces perinatal complications. However, metformin could impede pancreatic β cell development via impaired mitochondrial function. A new anti-diabetes drug imeglimin, developed based on metformin, improves mitochondrial function. Here …

jp (code pays fourni par la source)

Advances in glucagon research ~ 100th anniversary: invitation to the new ‘glucagon-ology’

Dan Kawamori

jp (code pays fourni par la source)

Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial

Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa et autres

BACKGROUND: This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes lacking an apparent history of cardiovascular disease. METHODS: This was a prospective …

jp (code pays fourni par la source)

Newly discovered knowledge pertaining to glucagon and its clinical applications

Dan Kawamori, Shugo Sasaki

Glucagon has been defined as an 'insulin counteracting hormone', which raises blood glucose levels. Recent progress in basic research has shown that glucagon is closely involved in glucose and amino acid metabolism. Additionally, its secretion is intricately, but precisely, regulated by various …

jp (code pays fourni par la source)

Different post-pancreatectomy glucagon responses to a meal test between surgical approaches

Tsuguka Matsuda, Natsumi Himeno, Akira Nakashima, Naoya Nakagawa et autres

Residual pancreatic endocrine function is important for maintaining metabolic status after pancreatectomy and is closely related to patient nutritional status and prognosis. In contrast to insulin secretion, the significance of glucagon secretion following pancreatectomy remains unclear. In this study, we assessed the …

jp (code pays fourni par la source)

Soluble T-cadherin promotes pancreatic β-cell proliferation by upregulating Notch signaling

Tomonori Okita, Shunbun Kita, Shiro Fukuda, Keita Fukuoka et autres

Endogenous humoral factors that link systemic and/or local insulin demand to pancreatic β-cells have not been identified. Here, we demonstrated that T-cadherin, a unique glycosylphosphatidylinositol-anchored cadherin primarily expressed in vascular endothelial cells and cardiac and skeletal muscle cells, but not in pancreatic …

jp (code pays fourni par la source)

Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes ( SURPASS J‐mono substudy)

Daisuke Yabe, Dan Kawamori, Yusuke Seino, Tomonori Oura et autres

Abstract Aim To evaluate the pharmacodynamic effects of tirzepatide, a novel dual glucagon‐like peptide‐1 receptor and glucose‐dependent insulinotropic polypeptide receptor agonist, compared with dulaglutide in patients with type 2 diabetes. Materials and Methods SURPASS J‐mono was a 52‐week, multicentre, randomized, double‐blind, parallel, …

jp (code pays fourni par la source)

Characteristic changes in plasma glutamate levels and free amino acid profiles in Japanese patients with type 1 diabetes mellitus

Dan Kawamori, Yoko Kageyama, Takayuki Tanaka, Yuko Ishizaka et autres

AIMS/INTRODUCTION: In addition to absolute insulin deficiency, dysregulated glucagon in type 1 diabetes is considered pathophysiologically important. Previously, we confirmed the presence of dysregulated glucagon in Japanese patients with type 1 diabetes, and found a significant correlation between plasma glucagon and blood …

jp (code pays fourni par la source)

Author response for "Change of pharmacodynamics parameters following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes ( SURPASS J‐mono sub‐study)"

Daisuke Yabe, Dan Kawamori, Yusuke Seino, Tomonori Oura et autres

The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus

Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa et autres

INTRODUCTION: Treatment-related quality of life (QOL) is an important aspect of diabetes management. We evaluated the influence of a sodium-glucose cotransporter 2 (SGLT2) inhibitor, tofogliflozin, on treatment-related QOL in Japanese patients with type 2 diabetes mellitus (T2DM). METHODS: This is the prespecified …

jp (code pays fourni par la source)